QNCX — Quince Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-05-09.
Performance
Technicals
Others in Healthcare
Measured signals that fired on QNCX
| date | signal | measured base rate |
|---|---|---|
| 2026-05-18 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-04-08 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-02-27 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-12-26 | Benatti Luca Director | Open-market sale | 50.0K | 3.47 | 173.5K |
| 2025-12-10 | Thye Dirk CEO and CMO | Gift | 739.9K | 0.00 | 0 |
| 2025-12-10 | Thye Dirk CEO and CMO | Gift | 739.9K | 0.00 | 0 |
| 2025-12-05 | Hannah Brendan CBO, COO & CCO | Option exercise | 25.3K | 0.94 | 23.8K |
| 2025-12-05 | Hannah Brendan CBO, COO & CCO | Option exercise | 2.3K | 0.55 | 1.2K |
| 2025-06-18 | Thye Dirk CEO and CMO | Grant or award | 150.9K | 1.20 | 181.1K |
| 2025-06-18 | Hannah Brendan CBO, COO & CCO | Grant or award | 37.7K | 1.20 | 45.3K |
| 2025-06-18 | Ryan Charles S. President | Grant or award | 7.5K | 1.20 | 9.1K |
| 2024-10-23 | Benatti Luca Director | Other Acquisition/Disposition | 8.9K | — | — |
| 2024-08-30 | Thye Dirk CEO AND CHIEF MEDICAL OFFICER | Open-market purchase | 77.0K | 0.70 | 53.9K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Woodline Partners LP | 527.3K | 5.2M |
| MILLENNIUM MANAGEMENT LLC | 253.9K | 2.5M |
| Shay Capital LLC | 179.8K | 1.8M |
| IEQ CAPITAL, LLC | 60.9K | 600.1K |
| BlackRock, Inc. | 48.0K | 473.3K |
| VANGUARD CAPITAL MANAGEMENT LLC | 46.6K | 461.5K |
| STATE STREET CORP | 25.1K | 248.0K |
| VANGUARD FIDUCIARY TRUST CO | 23.5K | 232.3K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 17.5K | 172.6K |
| SIMPLEX TRADING, LLC | 15.6K | 154.1K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K | 2026-08-17 | 2026-08-17 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| S-3/A | 2026-08-05 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Quince Therapeutics, Inc. (QNCX) filed form 8-K · 2026-08-17 · SEC EDGAR
- Quince Therapeutics, Inc. (QNCX) filed form 8-K · 2026-08-17 · SEC EDGAR
- Quince Therapeutics, Inc. (QNCX) filed form 8-K · 2026-08-14 · SEC EDGAR
- Quince Therapeutics GAAP EPS of -$12.31 misses by $0.02 · 2026-08-14
- Quince Therapeutics, Inc. (QNCX) filed form SCHEDULE 13G · 2026-08-14 · SEC EDGAR
- Quince Therapeutics, Inc. (QNCX) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
Ask the AI about QNCX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →